Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSTR

Go back to Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
(NASDAQ: NTLA) Delayed: 15.73 +0.06 (0.38%)
Previous Close $15.67    52 Week High $30.40 
Open $15.87    52 Week Low $11.86 
Day High $16.32    P/E N/A 
Day Low $15.57    EPS $0.00 
Volume 3,350,536